Background: Bacillus Calmette-Guérin (BCG) is one of the most successful vaccines in the world and evidence suggests it can be used as a bacterial vector to deliver heterologous antigens.

Objectives: We evaluated whether BCG could be biotinylated and used as a carrier of Schistosoma mansoni antigen tetraspanin-2 (TSP-2) fused with rhizavidin, an avidin analog.

Methods: BCG was grown and biotinylated. The recombinant protein Rzv:TSP-2 was produced and purified from Escherichia coli. The biotinylation and antigen coupling was analysed by flow cytometry, enzyme-linked immunosorbent assay (ELISA) and Western blot. Vaccine immunogenicity was tested in immunised mice by the assessment of lung and splenic T cells.

Findings: BCG can be biotinylated, which in turn, can be coupled with Rzv:TSP-2. After a series of optimisations which involved molarity of the biotin, ratio of BCG:reagent and the concentration of Rzv:TSP-2 used, almost 50% of the bacteria were biotinylated and 35% coupled with antigen. Although a clear adjuvant effect of BCG was observed, evaluation of immune response in immunised mice demonstrated an overall low immunogenicity of the BCG-Rzv:TSP-2.

Main Conclusion: These results demonstrated the use of BCG as a carrier of avidin-tagged antigens. Further optimisations are needed in order to strengthen the stability of tagged proteins in order to produce antigen-specific immune responses.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884745PMC
http://dx.doi.org/10.1590/0074-02760240167DOI Listing

Publication Analysis

Top Keywords

schistosoma mansoni
8
bcg biotinylated
8
immunised mice
8
bcg
6
exploring bcg
4
bcg deliver
4
deliver avidin
4
avidin fusion
4
fusion antigens
4
antigens schistosoma
4

Similar Publications

Background And Aims: Marked divergences in the immunological mechanisms that regulate the pathophysiology of acute and chronic schistosomiasis have a direct influence on pathological outcomes and antiparasitic chemotherapy responses at different stages of Schistosoma mansoni infection. In that way, this study evaluated the impact of combination antiparasitic chemotherapy, involving gentamicin (GEN) and doxycycline (DOX) in combination with praziquantel (PZQ) on the development of acute hepatic and intestinal schistosomiasis in mice.

Methods: BALB/cmice were randomized into five experimental groups, and the formation of hepatic and intestinal granulomas was evaluated by histopathological and histomorphometric analyses, quantification of hepatic parasite load, and biochemical parameters (ALT, AST, ALP, and albumin).

View Article and Find Full Text PDF

Exploring BCG to deliver avidin fusion antigens from Schistosoma mansoni.

Mem Inst Oswaldo Cruz

March 2025

Instituto Butantan, Laboratório de Desenvolvimento de Vacinas, São Paulo, SP, Brasil.

Background: Bacillus Calmette-Guérin (BCG) is one of the most successful vaccines in the world and evidence suggests it can be used as a bacterial vector to deliver heterologous antigens.

Objectives: We evaluated whether BCG could be biotinylated and used as a carrier of Schistosoma mansoni antigen tetraspanin-2 (TSP-2) fused with rhizavidin, an avidin analog.

Methods: BCG was grown and biotinylated.

View Article and Find Full Text PDF

Hymenolepis nana, commonly known as the dwarf tapeworm, affects 50 to 75 million people worldwide. To date, no studies have explored the disease burden of H. nana infection in Sudan.

View Article and Find Full Text PDF

Background: Schistosomiasis is a parasitic disease that causes coagulation disorders and biochemical abnormalities. This is due to liver failure, platelet destruction, disruption of blood flow, and endothelial function by the schistosomes. However, there is no adequate data on biochemical and coagulation profiles and platelet count of patients infected with Schistosoma mansoni in Dembiya Selected Health Institutions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!